Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade

Cancer Discovery

Volumn 6, Issue 8, 2016, Pages 827-837

  Chen, Pei Ling ^a   Roh, Whijae ^a   Reuben, Alexandre ^a   Cooper, Zachary A ^a,c   Spencer, Christine N ^a   Prieto, Peter A ^a   Miller, John P ^a   Bassett, Roland L ^a   Gopalakrishnan, Vancheswaran ^a   Wani, Khalida ^a   De Macedo, Mariana Petaccia ^a   Austin Breneman, Jacob L ^a   Jiang, Hong ^a   Chang, Qing ^a   Reddy, Sangeetha M ^a   Chen, Wei Shen ^a   Tetzlaff, Michael T ^a   Broaddus, Russell J ^a   Davies, Michael A ^a   Gershenwald, Jeffrey E ^a   Haydu, Lauren ^a   Lazar, Alexander J ^a   Patel, Sapna P ^a   Hwu, Patrick ^a   Hwu, Wen Jen ^a   Diab, Adi ^a   Glitza, Isabella C ^a   Woodman, Scott E ^a   Vence, Luis M ^a   Wistuba, Ignacio I ^a   Amaria, Rodabe N ^a   Kwong, Lawrence N ^a   Prieto, Victor ^a   Eric Davis, R ^a   Ma, Wencai ^a   Overwijk, Willem W ^a   Sharpe, Arlene H ^b   Hu, Jianhua ^a   Andrew Futreal, P ^a   Blando, Jorge ^a   Sharma, Padmanee ^a   Allison, James P ^a   Chin, Lynda ^a   Wargo, Jennifer A ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 INHIBITOR; GRANZYME B; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNE CHECKPOINT BLOCKADE; IMMUNE SIGNATURE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; SCORING SYSTEM; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOPSY; CLUSTER ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOMODULATION; MELANOMA; METABOLISM; NEOPLASMS; PROGNOSIS; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS; BIOPSY; CLUSTER ANALYSIS; CTLA-4 ANTIGEN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS;

EID: 84982946696     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1545     Document Type: Article

References (43)

1. Hodi FS., O’Day SJ., McDermott DF., Weber RW., Sosman JA., Haanen JB., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010. 363. 711–23.
2. Topalian SL., Hodi FS., Brahmer JR., Gettinger SN., Smith DC., McDermott DF., et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med 2012. 366. 2443–54.
3. Andtbacka RH., Kaufman HL., Collichio F., Amatruda T., Senzer N., Chesney J., et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33: 2780–8.
4. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob JJ., Cowey CL., Lao CD., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015. 373. 23–34.
5. Postow MA., Chesney J., Pavlick AC., Robert C., Grossmann K., McDermott D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015. 372. 2006–17.
6. Wolchok JD., Kluger H., Callahan MK., Postow MA., Rizvi NA., Lesokhin AM., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013. 369. 122–33.
7. Brahmer JR., Tykodi SS., Chow LQ., Hwu WJ., Topalian SL., Hwu P., et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012. 366. 2455–65.
8. Curti BD., Kovacsovics-Bankowski M., Morris N., Walker E., Chisholm L., Floyd K., et al. OX40 is a potent immune-stimulating target in latestage cancer patients. Cancer Res 2013. 73. 7189–98.
9. Topalian SL., Sznol M., McDermott DF., Kluger HM., Carvajal RD., Sharfman WH., et al. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014. 32. 1020–30.
10. Wolchok JD., Weber JS., Maio M., Neyns B., Harmankaya K., Chin K., et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013. 24. 2174–80.
11. Schadendorf D., Hodi FS., Robert C., Weber JS., Margolin K., Hamid O., et al. Pooled analysis of long-term survival data from phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015. 33. 1889–94.
12. Rizvi NA., Hellmann MD., Snyder A., Kvistborg P., Makarov V., Havel JJ., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124–8.
13. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky JM., Desrichard A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014. 371. 2189–99.
14. Tumeh PC., Harview CL., Yearley JH., Shintaku IP., Taylor EJ., Robert L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014. 515. 568–71.
15. Taube JM., Klein A., Brahmer JR., Xu H., Pan X., Kim JH., et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti–PD-1 therapy. Clin Cancer Res 2014. 20. 5064–74.
16. Van Allen EM., Miao D., Schilling B., Shukla SA., Blank C., Zimmer L., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015. 350. 207–11.
17. Hugo W., Zaretsky JM., Sun L., Song C., Moreno BH., Hu-Lieskovan S., et al. Genomic and transcriptomic features of response to anti–PD-1 therapy in metastatic melanoma. Cell 2016. 165. 35–44.
18. Gubin MM., Zhang X., Schuster H., Caron E., Ward JP., Noguchi T., et al. Checkpoint blockade cancer immunotherapy targets tumour-specifi c mutant antigens. Nature 2014. 515. 577–81.
19. Das R., Verma R., Sznol M., Boddupalli CS., Gettinger SN., Kluger H., et al. Combination therapy with anti–CTLA-4 and anti–PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015. 194. 950–9.
20. Koyama S., Akbay EA., Li YY., Herter-Sprie GS., Buczkowski KA., Richards WG., et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 2016. 7. 10501.
21. Rooney MS., Shukla SA., Wu CJ., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015. 160. 48–61.
22. Spranger S., Bao R., Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 2015. 523. 231–5.
23. Huang RR., Jalil J., Economou JS., Chmielowski B., Koya RC., Mok S., et al. CTLA4 blockade induces frequent tumor infi ltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res 2011. 17. 4101–9.
24. Ferrara N., Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005. 438. 967–74.
25. Voron T., Colussi O., Marcheteau E., Pernot S., Nizard M., Pointet AL., et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors. J Exp Med 2015. 212. 139–48.
26. Ott PA., Hodi FS., Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015. 5. 202.
27. Westin JR., Chu F., Zhang M., Fayad LE., Kwak LW., Fowler N., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014. 15. 69–77.
28. Motz GT., Santoro SP., Wang LP., Garrabrant T., Lastra RR., Hagemann IS., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014. 20. 607–15.
29. Ohm JE., Gabrilovich DI., Sempowski GD., Kisseleva E., Parman KS., Nadaf S., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003. 101. 4878–86.
30. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998. 92. 4150–66.
31. Terme M., Pernot S., Marcheteau E., Sandoval F., Benhamouda N., Colussi O., et al. VEGFA-VEGFR pathway blockade inhibits tumorinduced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013. 73. 539–49.
32. Hodi FS., Lawrence D., Lezcano C., Wu X., Zhou J., Sasada T., et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014. 2. 632–42.
33. Yuan J., Zhou J., Dong Z., Tandon S., Kuk D., Panageas KS., et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014. 2. 127–32.
34. Kageshita T., Hirai S., Ono T., Hicklin DJ., Ferrone S. Downregulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol 1999. 154. 745–54.
35. Shukla SA., Rooney MS., Rajasagi M., Tiao G., Dixon PM., Lawrence MS., et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 2015. 33. 1152–8.
36. Taube JM., Anders RA., Young GD., Xu H., Sharma R., McMiller TL., et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Translat Med 2012. 4. 127ra37.
37. Waggott D., Chu K., Yin S., Wouters BG., Liu FF., Boutros PC. NanoString- Norm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics 2012; 28: 1546–8.
38. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002. 3. Research0034.
39. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B (Methodological) 1995. 57. 289–300.
40. Pounds S., Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 2003. 19. 1236–42.
41. Bates D., Maechler M., Bolker B., Walker S. Fitting linear mixed-effects models using lme4. J Stat Software 2015; 67: 1–48.
42. O’Connor CM., Sheppard S., Hartline CA., Huls H., Johnson M., Palla SL., et al. Adoptive T-cell therapy improves treatment of canine non- Hodgkin lymphoma post chemotherapy. Sci Rep 2012. 2. 249.
43. Ma W., Yang D., Gu Y., Guo X., Zhao W., Guo Z. Finding disease-specific coordinated functions by multi-function genes: insight into the coordination mechanisms in diseases. Genomics 2009. 94. 94–100.